Sum Up The Pieces: EQAL Could Be Worth $56
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Should l Buy LH?
Source: NASDAQ.COM
ETF Analyst Target Price Insights: The Invesco Russell 1000 Equal Weight ETF (EQAL) has an implied analyst target price of $55.81, indicating a potential upside of 10.57% from its current trading price of $50.47.
Notable Holdings with Upside Potential: Key underlying holdings such as Live Nation Entertainment Inc., Kinder Morgan Inc., and Labcorp Holdings Inc. show significant upside potential based on analysts' target prices, suggesting further investor research is warranted to assess the validity of these targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 278.110
Low
270.00
Averages
304.45
High
325.00
Current: 278.110
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Labcorp to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Labcorp Holdings (LH) is set to announce its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $3.94, reflecting a 14.2% year-over-year growth, indicating sustained profitability potential for the company.
- Revenue Expectations: The anticipated revenue for Q4 is $3.56 billion, representing a 6.9% year-over-year increase, which underscores the stable demand in the medical testing sector and potential market share gains, likely boosting investor confidence moving forward.
- Historical Performance Review: Over the past two years, Labcorp has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing the company's reliability in financial performance and enhancing market confidence in its future results.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates have also experienced 2 upward and 3 downward revisions, indicating market uncertainty regarding the company's future performance, which investors should monitor closely ahead of the earnings release.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
Labcorp Launches Alzheimer's Blood Test Nationwide
- Innovative Testing Tool: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for initial Alzheimer's disease assessment, enabling clinicians to rule out patients' Alzheimer's likelihood more quickly, thereby enhancing patient care efficiency.
- Wide Applicability: The test is now available nationwide in primary care settings, specifically designed for patients aged 55 and older experiencing cognitive decline symptoms, significantly expanding Labcorp's comprehensive portfolio of Alzheimer's blood tests.
- High Predictive Capability: The Elecsys pTau-181 test offers a 97.9% negative predictive value, allowing clinicians to confidently rule out Alzheimer's pathology, which is crucial in reducing unnecessary referrals amid a national shortage of neurologists.
- Convenient Testing Method: The test is performed via a simple blood draw, which can be done in a doctor's office or at any of Labcorp's over 2,200 patient service centers, providing a more accessible and cost-effective alternative to traditional brain scans or lumbar punctures.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Labcorp to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Labcorp Holdings (LH) is set to announce its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $3.94, reflecting a 14.2% year-over-year growth, indicating sustained profitability potential for the company.
- Revenue Expectations: The anticipated revenue for Q4 is $3.56 billion, representing a 6.9% year-over-year increase, which underscores the stable demand in the medical testing sector and potential market share gains, likely boosting investor confidence moving forward.
- Historical Performance Review: Over the past two years, Labcorp has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing the company's reliability in financial performance and enhancing market confidence in its future results.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates have also experienced 2 upward and 3 downward revisions, indicating market uncertainty regarding the company's future performance, which investors should monitor closely ahead of the earnings release.
See More
Labcorp Launches First Blood Test for Alzheimer's Disease
- First Blood Test: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for the initial assessment of Alzheimer's disease, representing a significant breakthrough in primary care that enables earlier identification of patient conditions.
- Expanded Testing Access: This test allows primary care clinicians to quickly rule out Alzheimer's disease when patients present cognitive symptoms, thereby enhancing patient care efficiency and reducing reliance on specialists, optimizing healthcare resource allocation.
- Market Demand Response: With approximately 7.2 million Americans living with Alzheimer's disease, Labcorp's launch of this test addresses the urgent need for early diagnosis and assessment, further solidifying its leadership position in the blood testing market for Alzheimer's disease.
- Research Support: Labcorp has supported over 90 Alzheimer's disease research protocols in the past five years, showcasing its deep expertise in biomarker development aimed at advancing early diagnosis and treatment progress for Alzheimer's disease.
See More
Labcorp Launches Alzheimer's Blood Test Nationwide
- Innovative Testing Tool: Labcorp's Elecsys® pTau-181 test is the first blood test cleared by the FDA for initial Alzheimer's disease assessment, enabling clinicians to rule out patients' Alzheimer's likelihood more quickly, thereby enhancing patient care efficiency.
- Wide Applicability: The test is now available nationwide in primary care settings, specifically designed for patients aged 55 and older experiencing cognitive decline symptoms, significantly expanding Labcorp's comprehensive portfolio of Alzheimer's blood tests.
- High Predictive Capability: The Elecsys pTau-181 test offers a 97.9% negative predictive value, allowing clinicians to confidently rule out Alzheimer's pathology, which is crucial in reducing unnecessary referrals amid a national shortage of neurologists.
- Convenient Testing Method: The test is performed via a simple blood draw, which can be done in a doctor's office or at any of Labcorp's over 2,200 patient service centers, providing a more accessible and cost-effective alternative to traditional brain scans or lumbar punctures.
See More
Labcorp Appoints New Board Member
- New Board Member: Labcorp appointed Dr. John H. Sampson to its Board of Directors effective February 9, 2026, bringing extensive experience in medicine and biomedical research, which is expected to advance the company's strategy in diagnostics and drug development.
- Professional Background: Dr. Sampson previously served as vice chancellor and dean at the University of Colorado Anschutz School of Medicine and held senior roles at Duke University Health System, with nearly 300 peer-reviewed publications showcasing his expertise in advancing new therapies for neurologic diseases.
- Strategic Alignment: His deep expertise in oncology, neuroscience, and personalized medicine aligns closely with Labcorp's strategic focus, likely enhancing the value delivered to customers.
- Quality Compliance Committee: Following his appointment, Dr. Sampson was also appointed to the Quality and Compliance Committee, further strengthening Labcorp's leadership in quality management and compliance.
See More
